Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J7MQ
|
||||
| Former ID |
DIB000865
|
||||
| Drug Name |
MKC-1106-MT
|
||||
| Synonyms |
Melanoma vaccine (MART-1/tyrosinase), Mannkind
|
||||
| Indication | Melanoma [ICD9: 172; ICD10:C43] | Phase 2 | [1] | ||
| Company |
Colby pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | MART-1 melanoma antigen | Target Info | Modulator | [2] | |
| Tyrosine oxidase | Target Info | Modulator | [2] | ||
| BioCyc Pathway | (S)-reticuline biosynthesis | ||||
| Eumelanin biosynthesis | |||||
| L-dopachrome biosynthesis | |||||
| KEGG Pathway | Tyrosine metabolism | ||||
| Riboflavin metabolism | |||||
| Metabolic pathways | |||||
| Melanogenesis | |||||
| PathWhiz Pathway | Riboflavin Metabolism | ||||
| Tyrosine Metabolism | |||||
| WikiPathways | Dopamine metabolism | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.